Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGF...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Masuzawa, Keita, Yasuda, Hiroyuki, Hamamoto, Junko, Nukaga, Shigenari, Hirano, Toshiyuki, Kawada, Ichiro, Naoki, Katsuhiko, Soejima, Kenzo, Betsuyaku, Tomoko
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739653/
https://ncbi.nlm.nih.gov/pubmed/29285266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22297
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares